US FDA may approve Covid-19 booster without outside advisory panel opinion -CNN
Pfizer and BioNTech on Tuesday requested the FDA to authorize booster doses of their Covid-19 vaccine in all adults
The U.S. Food and Drug Administration is unlikely to ask its outside vaccine advisers to weigh in on whether the agency should authorize Pfizer Covid-19 boosters for all adults, CNN reported on Friday, citing a source.
The source told CNN "it's unlikely there is going to be a meeting" of the outside advisers and "there has been no discussion of a meeting" to discuss Pfizer's application.
The FDA said the agency "will determine whether to hold a meeting of the advisory committee ... following its initial review of the information submitted," CNN added.
Keep updated, follow The Business Standard's Google news channel
Pfizer and BioNTech on Tuesday requested the FDA to authorize booster doses of their Covid-19 vaccine in all adults, presenting data showing the shot would help prevent disease across ages.
Over the past several months, the FDA has authorized Pfizer's boosters for people who are immunocompromised, those who are aged 65 and above, all people at high risk of severe disease, and people who are regularly exposed to the virus.
